
COGT Stock Forecast & Price Target
COGT Analyst Ratings
Bulls say
Cogent Biosciences is a promising biotechnology company with a selective tyrosine kinase inhibitor that targets the underlying cause of Systemic Mastocytosis (SM) and advanced gastrointestinal stromal tumors (GIST). However, there are risks to the attainment of our rating and price target, including potential downward adjustments in market penetration due to poor clinical results, emergence of better-than-expected competitor products, and regulatory/commercial risks. These may result in a longer horizon to approval or preclusion of approval, as well as a change in fair value of their Contingent Value Right liability.
Bears say
Cogent Biosciences is expected to experience increased revenues in the near future due to potential FDA approvals for its precision therapies, specifically bezuclastinib, in multiple indications such as systemic mastocytosis and gastrointestinal stromal tumors. Despite a strong balance sheet and potential for future growth, the company remains a high-risk investment due to the uncertain success of its pipeline and potential competition from other companies. Additionally, the negative earnings reported in the recent quarter and projected losses for the full year may also be cause for concern for potential investors.
This aggregate rating is based on analysts' research of Cogent Biosciences, Inc. and is not a guaranteed prediction by Public.com or investment advice.
COGT Analyst Forecast & Price Prediction
Start investing in COGT
Order type
Buy in
Order amount
Est. shares
0 shares